Skip to content
Welcome, thoughtbot's Giant Robots listeners!Start here
UK Startups and Innovation
14NOV

T-Therapeutics raises $133m in Series B

2 min read
18:53UTC

The British Business Bank put £15m into Cambridge spinout T-Therapeutics' $133m Series B and took a board seat beside co-lead Advent Life Sciences.

TechnologyAssessed
Key takeaway

The British Business Bank co-led T-Therapeutics' round and took a board seat.

The British Business Bank put £15m into a $133m Series B for T-Therapeutics, a University of Cambridge spinout, announced on Thursday 5 November. Advent Life Sciences and the Bank co-led the round, and the Bank takes a board seat⁠1. The Bank calls it its third co-investment beside Advent, and it also holds an indirect stake through Cambridge Innovation Capital's second fund⁠2. Eli Lilly, Johnson & Johnson Innovation, Samsara BioCapital and M Ventures, the venture arm of Germany's Merck KGaA, joined; existing backers including Sofinnova Partners returned⁠3.

The money takes two T-cell receptor bispecifics towards clinical proof of concept, one in cancer and one in autoimmune disease. Each molecule grips a marker on a diseased cell with one arm and pulls in a T cell, the immune system's killer cell, with the other. The Bank led Microbiotica's round in October and followed in OMass's; with T-Therapeutics it is co-leading and sitting on the board.

Deep Analysis

In plain English

T-Therapeutics is a young drug company that came out of research at the University of Cambridge. It is designing drugs with two arms. One arm grabs a diseased cell. The other pulls in a T cell, the immune system's killer cell, so it destroys the diseased one. The company has raised $133m to start testing two of these drugs in people, one for cancer and one for diseases where the immune system attacks the body. A government-owned bank is one of the investors.

Deep Analysis
Root Causes

Antibody drugs can only reach proteins on the outside of a cell. Most cancer-driving proteins sit inside, and T-cell receptors can detect fragments of them displayed on the surface. That gap is why large drugmakers keep buying into the field.

Cambridge spinouts need far more money than British venture funds can supply alone to reach human trials. The register mixes Advent, the British Business Bank, Eli Lilly, Johnson & Johnson's JJDC, Sanofi Ventures and the Chinese technology group Tencent, because no single investor class will fund drug development to proof of concept.

What could happen next?
  • Consequence

    The British Business Bank's board seat gives the state a direct voice in a drug developer's clinical decisions.

    Short term · Assessed
  • Opportunity

    Early human data could draw licensing offers from the drugmakers already on the register.

    Medium term · Suggested
  • Risk

    Tissue-type restrictions may limit each drug to a subset of patients, as with Kimmtrak.

    Long term · Suggested
First Reported In

Update #17 · Founders' relief built for 600 a year

BioPharm International· 14 Nov 2026
Read original →
Causes and effects
This Event
T-Therapeutics raises $133m in Series B
The Business Bank is now co-leading biotech rounds with a board seat, acting as a direct investor rather than only a backer of funds.
Different Perspectives
Association of Investment Companies (Richard Stone)
Association of Investment Companies (Richard Stone)
The trust industry body criticised the Budget for leaving Venture Capital Trust relief at 20%. It had lobbied for the 30% rate to return.
Tax Justice UK
Tax Justice UK
The campaign group opposed the 10% founders' rate as a giveaway to a small group of wealthy owners. It said the BADR cut should have gone further, to abolition.
techUK
techUK
The trade body set the new relief against the BADR cut, which halves the most a seller can save to £30,000. It says the Budget takes back with BADR part of what it gives founders.
Startup Coalition
Startup Coalition
The founder lobby group welcomed the Budget package for startups. It treats the new relief as the strongest government support for founders in years.
HM Treasury
HM Treasury
The Treasury created a 10% founders' relief on up to £10m of lifetime gains and expects about 600 people a year to use it. It says the relief rewards founders behind the UK's fastest-growing companies.
Abu Dhabi Investment Council
Abu Dhabi Investment Council
The Abu Dhabi Investment Council holds notes in Nscale's $3.36bn pre-IPO raise, beside Third Point, Apollo, Citadel and Nvidia. No British institution appears among the named holders of notes that convert into shares at Nscale's New York listing.

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Editorial standards.